TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06423755

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swimming programme
Description: A session plan will be followed, which included aims, objectives, learning outcomes and suggested core aquatic skills and swimming activities under each section. The session will consist of a session brief, a warmup, core aquatic skills, swimming strokes (front crawl, backstroke, breaststroke, and hybrid strokes), a cool down and a session debrief; following the guidance developed in study three.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physiotherapy care
Description: Treatment delivered by the physiotherapist could include exercise, advice, education, and manual therapy; they will be offered up to 6 sessions.
Study: NCT05200130

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercise Group
Description: The home exercise program includes an educational training program and posture correction exercises. The program includes stretching and strengthening exercises of the neck and shoulder complex.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy Group
Description: Manual Therapy includes deep friction massage and myofascial relaxation techniques to shoulder and neck complex, active and resistant shoulder complex movements, shoulder complex mobilization, mobilization cervical joints.~The home exercise program includes an educational training program and posture correction exercises. The program includes stretching and strengthening exercises of the neck and shoulder complex.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation Group
Description: The telerehabilitation program applied to the same home exercise group. In addition, to the home exercises, these patients will apply active mobilization called self-mobilization. Self-myofascial release, active glenohumeral joint mobilization, thoracic mobilization, and active cervical mobilization.
Study: NCT06397599

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: denture adhesive
Description: use of adhesive for completely edentulous

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: denture adhesive
Description: use of adhesive for completely edentulous
Study: NCT06356025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botulinum toxin type A
Description: Botulinum toxin type A 75U dissolved in 3mL physiological serum injection in the upper esophageal sphincter

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9% Inj
Description: Placebo: physiological serum 3mL injection in the upper esophageal sphincter
Study: NCT05009108

Intervention type: DIAGNOSTIC_TEST
Intervention: Purdue Pegboard Test
Description: At first, each person will be asked to fill in the informed agreement and answer short questionnaire. Than he/she will be tested by the Purdue Pegboard Test according to the Czech version of extended manuals for those tests in only one session. Audio recording of verbal instructions will be used and whole testing process will be video recorded which is necessary for establishing the internal variability and variability of results of the Purdue Pegboard Test.~The results will be used only for establishing of the variability and inter-rater reliability of the Purdue Pegboard Test, not for patients' other interventions.
Study: NCT06181110

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Intervention for Sleep and Circadian Dysfunction
Description: This intervention is a non-pharmacological approach that targets various factors contributing to sleep and circadian problems. It incorporates evidence-based elements such as CBT for insomnia, IPSRT, chronotherapy, and motivation enhancement. The treatment consists of 8 sessions with 4 cross-cutting modules: case formulation, sleep and circadian education, motivational interviewing, and goal setting. Participants also receive 4 core modules addressing sleep-wake regularity, daytime functioning, correcting beliefs, and maintaining behavioral change. Additionally, 6 optional modules cater to specific sleep-wake patterns, addressing sleep efficiency, excessive time in bed, delayed/advanced sleep phase, sleep-related worry, complex sleep environments, and nightmares. Modules are delivered based on individual needs. Sessions include agenda setting, homework review, treatment content delivery, goal assignment, and session summarization.
Study: NCT06150703

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ovulation induction with hCG + Luteal phase support with vaginal progesterone
Description: hCG 250µg subcutaneously between 36h and 38h before oocyte retrieval + Progesterone 600mg/d (200mg morning, noon and evening) vaginally from the evening of the puncture until the pregnancy test result

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ovulation triggering by Triptorelin + Luteal phase support by Nafarelin
Description: Triptorelin 0.2 mg subcutaneously between 36h and 38h before oocyte retrieval as a single dose Nafarelin 400µg /day (200µg in the morning 200µg in the evening) nasally from the evening of the oocyte retrieval until the first pregnancy test
Study: NCT05152732

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: VGB-R04
Description: A novel, bioengineered adeno-associated viral (AAV) vector carrying human factor IX variant
Study: NCT04911309

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: functional exercise training
Description: 12 weeks functional exercise training twice per week, each session lasting 60 min

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: functional exercise training
Description: 12 weeks functional exercise training twice per week, each session lasting 60 min

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard therapy / treatment
Description: 12 weeks standard therapy / treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard therapy / treatment
Description: 12 weeks standard therapy / treatment
Study: NCT05775588

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery with endobronchial valve implantation
Description: the patient would undergo Lung volume reduction surgery with endobronchial valve implantation
Study: NCT05873374

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 50 μg Baiya SARS-CoV-2 Vax 2
Description: Intramuscular injection in the deltoid region of 0.5 mL/dose of 50 μg Baiya SARS-CoV-2 Vax 2

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection in the deltoid region of 0.5 mL/dose of 0.9% Sodium Chloride
Study: NCT05605210

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric stimulation
Description: Neuromuscular electrical stimulation will be applied at two sites to induce fatigue with stimulation frequency specified at the Arm/Group Descriptions. The electrical stimulation parameters to generate the fatigue protocol will be: biphasic pulsed current, pulse duration of 2 ms, and on:off times of 5:10s. The fatigue protocol will be applied with a current intensity sufficient to generate an evoked torque at a level of 20% of the MVIC, which will be maintained throughout the protocol. NMES will be maintained until reaching an intervention time of 20 minutes, generating 80 evoked contractions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric stimulation
Description: Neuromuscular electrical stimulation will be applied at two sites to induce fatigue with stimulation frequency specified at the Arm/Group Descriptions. The electrical stimulation parameters to generate the fatigue protocol will be: biphasic pulsed current, pulse duration of 2 ms, and on:off times of 5:10s. The fatigue protocol will be applied with a current intensity sufficient to generate an evoked torque at a level of 20% of the MVIC, which will be maintained throughout the protocol. NMES will be maintained until reaching an intervention time of 20 minutes, generating 80 evoked contractions.
Study: NCT05642156

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: isolated Ultrafiltration (iso-UF)
Description: isolated Ultrafiltration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: isolated Ultrafiltration (iso-UF)
Description: isolated Ultrafiltration
Study: NCT05157321

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: TMS device will deliver repetitive trains of magnetic pulses using Magstim Rapid 2 with angulated figure of eight shaped coil. The device comprised two-channel Neuro-EMG-MS digital system for determining the motor threshold of the patients that will be used for establishing the threshold intensity for stimulation. The figure of eight-shaped coil generated a magnetic field of up to 4 Tesla that penetrates the cranium, enters into the soft tissue of the brain and henceforth stimulates the motor neurons.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive Transcranial Magnetic Stimulation
Description: Sham Repetitive Transcranial Magnetic Stimulation
Study: NCT05605210

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric stimulation
Description: Neuromuscular electrical stimulation will be applied at two sites to induce fatigue with stimulation frequency specified at the Arm/Group Descriptions. The electrical stimulation parameters to generate the fatigue protocol will be: biphasic pulsed current, pulse duration of 2 ms, and on:off times of 5:10s. The fatigue protocol will be applied with a current intensity sufficient to generate an evoked torque at a level of 20% of the MVIC, which will be maintained throughout the protocol. NMES will be maintained until reaching an intervention time of 20 minutes, generating 80 evoked contractions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric stimulation
Description: Neuromuscular electrical stimulation will be applied at two sites to induce fatigue with stimulation frequency specified at the Arm/Group Descriptions. The electrical stimulation parameters to generate the fatigue protocol will be: biphasic pulsed current, pulse duration of 2 ms, and on:off times of 5:10s. The fatigue protocol will be applied with a current intensity sufficient to generate an evoked torque at a level of 20% of the MVIC, which will be maintained throughout the protocol. NMES will be maintained until reaching an intervention time of 20 minutes, generating 80 evoked contractions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric stimulation
Description: Neuromuscular electrical stimulation will be applied at two sites to induce fatigue with stimulation frequency specified at the Arm/Group Descriptions. The electrical stimulation parameters to generate the fatigue protocol will be: biphasic pulsed current, pulse duration of 2 ms, and on:off times of 5:10s. The fatigue protocol will be applied with a current intensity sufficient to generate an evoked torque at a level of 20% of the MVIC, which will be maintained throughout the protocol. NMES will be maintained until reaching an intervention time of 20 minutes, generating 80 evoked contractions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric stimulation
Description: Neuromuscular electrical stimulation will be applied at two sites to induce fatigue with stimulation frequency specified at the Arm/Group Descriptions. The electrical stimulation parameters to generate the fatigue protocol will be: biphasic pulsed current, pulse duration of 2 ms, and on:off times of 5:10s. The fatigue protocol will be applied with a current intensity sufficient to generate an evoked torque at a level of 20% of the MVIC, which will be maintained throughout the protocol. NMES will be maintained until reaching an intervention time of 20 minutes, generating 80 evoked contractions.
Study: NCT05842512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-PEG20
Description: Treatment for NASH

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment for NASH
Study: NCT06580379

Intervention type: PROCEDURE
Intervention: Spine surgery
Description: Spine surgery, such as fusion requiring the need for precise intraoperative registration and navigation
Study: NCT06471634

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBTi
Description: A 12 week intervention using CBTi to improve sleep measured using objective and subjective measures. Participants will complete a number of questionnaires and tests at baseline and at completion to allow comparisons to be made.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control - usual care
Description: Participants will be given a leaflet summarising good sleep practice and the advantages of reducing sedentary behaviour. Participants will complete a number of questionnaires and tests at baseline and at completion to allow comparisons to be made.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedentary behaviour reduction
Description: Participants will be encouraged to increase activity and thus reduce sedentary time. Investigators will use behaviour change techniques to aid in this goal. Participants will complete a number of questionnaires and tests at baseline and at completion to allow comparisons to be made.
Study: NCT06497894

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy for Insomnia (CBT-I)
Description: CBT-I is conducted in an individual setting according to the manual used in McCurry (1). Factors at the level of behavior, cognitions, and physiology that perpetuate sleep onset and sleep maintenance disorders are addressed. In addition, psychoeducation on sleep and sleep hygiene, stimulus control, sleep restriction, relaxation, structured worry time, cognitive restructuring, and relapse prevention are part of the training. Each session will include homework.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hormone Replacement Therapy (HRT)
Description: Standard-dose continuously-combined bio-identical HRT containing transdermal estradiol 1.5 mg/d (= 2 strokes of Oestrogel® Dispenser) and oral micronized progesterone (= 1 capsule of Utrogestan® 200). This combination is the most popular HRT regimen, as it has a neutral effect on lipids, glucose, haemostasis. Participants will receive a conventional prescription for the 2 products that are covered by all health insurances in Switzerland.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sleep Hygiene
Description: Sleep hygiene refers to healthy sleep habits, e.g. food and drink choices, a regular sleep schedule, evening routine. Although being widely used in daily practice, sleep hygiene shows no significant effect as monotherapy in patients with an established insomnia. The sleep hygiene condition in this study is matched to CBT-I in frequency and intensity of contact.
Study: NCT04620967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Description: Insulin aspart (Iasp) in insulin pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Description: Insulin aspart (Iasp) in insulin pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fast-acting insulin aspart
Description: Fast-acting insulin aspart (Fiasp) in insulin pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fast-acting insulin aspart
Description: Fast-acting insulin aspart (Fiasp) in insulin pump
Study: NCT06072703

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magstim Rapid2 System
Description: The Magstim Rapid2 system is the most commonly used magnetic stimulation system for rTMS clinical studies and therapeutic investigations, capable of selectively inducing, modulating or suppressing neuronal activity. This rTMS device will be used along with the D70 Alpha Coil package, which includes an active coil ideal for focal rTMS and a sham coil, The placebo coil looks identical to its active version and replicates pulse noise without producing the magnetic field necessary to modulate cortical neurons. Additionally, the investigators will be utilizing the StimGuide navigation system (currently available at the HMRI) to accurately target the proposed regions of interest.~The Magstim Rapid2 system is indicated to be used in Multiple Sclerosis patients as target users with lower urinary tract symptoms such as urinary frequency, urinary urgency, urinary incontinence and voiding dysfunction.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Magstim Rapid2 System
Description: The Magstim Rapid2 system is the most commonly used magnetic stimulation system for rTMS clinical studies and therapeutic investigations, capable of selectively inducing, modulating or suppressing neuronal activity. This rTMS device will be used along with the D70 Alpha Coil package, which includes an active coil ideal for focal rTMS and a sham coil, The placebo coil looks identical to its active version and replicates pulse noise without producing the magnetic field necessary to modulate cortical neurons. Additionally, the investigators will be utilizing the StimGuide navigation system (currently available at the HMRI) to accurately target the proposed regions of interest.~The Magstim Rapid2 system is indicated to be used in Multiple Sclerosis patients as target users with lower urinary tract symptoms such as urinary frequency, urinary urgency, urinary incontinence and voiding dysfunction.
Study: NCT05413980

Intervention type: OTHER
Intervention: Moxifloxacin hydrochloride ophthalmic solution
Description: Prospective observational study. There is no treatment allocation. Patients prescribed with 0.5% Moxifloxacin hydrochloride ophthalmic solution during the perioperative period of ophthalmic surgery are eligible to enroll into this study.
Study: NCT04851548

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hyaluronic acid
Description: after flap refection, the furcation area will be debrided then add hyaluronic acid 8% and cover it with a collagen membrane

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hyaluronic acid
Description: after flap refection, the furcation area will be debrided then add hyaluronic acid 8% and cover it with a collagen membrane
Study: NCT05499130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-48574
Description: Subcutaneous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-48574
Description: Subcutaneous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-48574
Description: Subcutaneous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-48574
Description: Subcutaneous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study: NCT04899778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Contraceptive Pill, norethindrn a-e estradiol-iron
Description: tablet
Study: NCT05074082

Intervention type: PROCEDURE
Intervention: Flap reconstruction
Description: Formation of a (myo-/fascio-)cutaneous flap for repair of a skin and soft tissue defect
Study: NCT04732299

Intervention type: OTHER
Intervention: MRI examination
Description: Magnetic resonance thrombography is used to determine the location of thrombus, quantify the thrombus and determine its stage.

Intervention type: OTHER
Intervention: MRI examination
Description: Magnetic resonance thrombography is used to determine the location of thrombus, quantify the thrombus and determine its stage.

Intervention type: OTHER
Intervention: MRI examination
Description: Magnetic resonance thrombography is used to determine the location of thrombus, quantify the thrombus and determine its stage.
Study: NCT05065879

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVAX
Description: 2 doses of Covid-19 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVAX
Description: 2 doses of Covid-19 vaccine
Study: NCT05255432

Intervention type: OTHER
Intervention: nil intervention
Description: Users observation using medical device on manakin, different scenarios per group

Intervention type: OTHER
Intervention: nil intervention
Description: Users observation using medical device on manakin, different scenarios per group
Study: NCT05003102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride - Cycling
Description: Dexmedetomidine Hydrochloride infusion at 0.5 mcg/kg titrated to 0.3 mcg/kg/hr up to a max drip rate of 2 mcg/kg/hr.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Hydrochloride - Cycling
Description: Dexmedetomidine Hydrochloride infusion at 0.5 mcg/kg titrated to 0.3 mcg/kg/hr up to a max drip rate of 2 mcg/kg/hr.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl - PICU Standard
Description: fentanyl infusion at 1 mcg/kg/hr up to a max drip rate of 5 mcg/kg/hr

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl - PICU Standard
Description: fentanyl infusion at 1 mcg/kg/hr up to a max drip rate of 5 mcg/kg/hr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride - PICU Standard
Description: Dexmedetomidine Hydrochloride infusion at 0.3 mcg/kg titrated to 0.5 mcg/kg/hr up to a max drip rate of 2 mcg/kg/hr

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Hydrochloride - PICU Standard
Description: Dexmedetomidine Hydrochloride infusion at 0.3 mcg/kg titrated to 0.5 mcg/kg/hr up to a max drip rate of 2 mcg/kg/hr
Study: NCT05065879

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVAX
Description: 2 doses of Covid-19 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVAX
Description: 2 doses of Covid-19 vaccine
Study: NCT06225570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: This arm aims to study the effectiveness, side effects and patient satisfaction of taking isotretinoin on a weekly basis as opposed to current standard daily dosing.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline
Description: This arm aims to serve as the comparison group. Tetracycline antibiotics are the current standard of care for the treatment of moderate acne.
Study: NCT05621746

Intervention type: DRUG
Intervention: Esperoct
Description: Participants will be treated with commercially available Esperoct for a total study duration of 24 months according to the local label and local routine clinical practice at the discretion of the physician. The decision to switch to Esperoct will be made prior to and separate from the decision to enrol in the study.
Study: NCT04971135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAN711
Description: SAN711 liquid formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAN711
Description: SAN711 liquid formulation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT05971121

Intervention type: DRUG
Intervention: ciprofol
Description: Ciprofol were used for sedation in ICU hypotensive patients
Study: NCT05771337

Intervention type: DIAGNOSTIC_TEST
Intervention: blood sample
Description: blood sample

Intervention type: DIAGNOSTIC_TEST
Intervention: blood sample
Description: blood sample